Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AMC NASDAQ:DKNG NASDAQ:EIDX NASDAQ:HMSY NYSE:NCLH NASDAQ:REAL NASDAQ:REGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMCAMC Entertainment$3.49+9.9%$3.13$2.45▼$5.76$1.37B1.4311.28 million shs22.93 million shsDKNGDraftKings$43.94+1.3%$38.82$28.69▼$53.61$38.56B1.679.68 million shs8.89 million shsEIDXEidos Therapeutics$122.21$123.21$28.39▼$132.54$4.75B-0.16128,113 shsN/AHMSYHMS$36.98$36.92$23.12▼$37.22$3.28B0.811.44 million shsN/ANCLHNorwegian Cruise Line$23.60+2.4%$19.58$14.21▼$29.29$10.30B2.1312.98 million shs12.11 million shsREALRealReal$5.64+8.0%$5.30$2.24▼$11.38$590.35M2.462.89 million shs4.52 million shsREGNRegeneron Pharmaceuticals$550.00+0.4%$544.14$476.49▼$1,211.20$59.16B0.33920,632 shs989,175 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMCAMC Entertainment+9.36%+15.89%+15.24%+25.32%-35.65%DKNGDraftKings+1.34%-1.41%+15.27%+30.73%+14.58%EIDXEidos Therapeutics0.00%0.00%0.00%0.00%0.00%HMSYHMS0.00%0.00%0.00%0.00%0.00%NCLHNorwegian Cruise Line+2.40%+1.81%+30.05%+44.02%+18.82%REALRealReal+8.05%+3.87%+9.09%+4.83%+49.60%REGNRegeneron Pharmaceuticals+0.38%-1.74%+8.08%-2.34%-49.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMCAMC Entertainment2.3289 of 5 stars1.91.00.03.52.70.00.6DKNGDraftKings3.9614 of 5 stars3.52.00.00.02.72.51.9EIDXEidos TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHMSYHMSN/AN/AN/AN/AN/AN/AN/AN/ANCLHNorwegian Cruise Line4.2854 of 5 stars2.42.00.01.22.71.74.4REALRealReal1.7238 of 5 stars3.41.00.00.02.51.70.0REGNRegeneron Pharmaceuticals4.7859 of 5 stars4.43.01.72.32.11.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMCAMC Entertainment 1.88Reduce$4.2622.05% UpsideDKNGDraftKings 2.96Moderate Buy$54.1023.13% UpsideEIDXEidos Therapeutics 0.00N/AN/AN/AHMSYHMS 0.00N/AN/AN/ANCLHNorwegian Cruise Line 2.71Moderate Buy$25.427.73% UpsideREALRealReal 2.86Moderate Buy$8.3347.75% UpsideREGNRegeneron Pharmaceuticals 2.80Moderate Buy$814.5748.10% UpsideCurrent Analyst Ratings BreakdownLatest REGN, DKNG, EIDX, NCLH, HMSY, AMC, and REAL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/18/2025DKNGDraftKingsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$51.007/17/2025REALRealRealB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.007/16/2025DKNGDraftKingsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$53.00 ➝ $51.007/16/2025DKNGDraftKingsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$50.00 ➝ $55.007/16/2025NCLHNorwegian Cruise LineCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$25.00 ➝ $30.007/15/2025DKNGDraftKingsBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.00 ➝ $50.007/11/2025DKNGDraftKingsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy7/11/2025AMCAMC EntertainmentWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Outperform$3.00 ➝ $4.007/11/2025DKNGDraftKingsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$51.00 ➝ $52.007/11/2025REGNRegeneron PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$560.00 ➝ $584.007/10/2025REGNRegeneron PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$755.00 ➝ $754.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMCAMC Entertainment$4.64B0.33N/AN/A($4.25) per share-0.82DKNGDraftKings$4.77B8.20N/AN/A$1.15 per share38.21EIDXEidos Therapeutics$26.69M177.99N/AN/A$4.57 per share26.74HMSYHMS$626.40M5.23$1.68 per share22.06$9.70 per share3.81NCLHNorwegian Cruise Line$9.48B1.11$4.24 per share5.57$3.24 per share7.28REALRealReal$600.48M1.06N/AN/A($3.71) per share-1.52REGNRegeneron Pharmaceuticals$14.20B4.18$45.87 per share11.99$268.50 per share2.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMCAMC Entertainment-$352.60M-$0.98N/AN/AN/A-8.60%N/A-5.68%8/1/2025 (Estimated)DKNGDraftKings-$507.29M-$0.83N/A28.721.37-7.97%-34.55%-8.51%7/30/2025 (Estimated)EIDXEidos Therapeutics-$37.83M-$1.03N/AN/AN/AN/A-65.21%-53.04%N/AHMSYHMS$87.22M$1.1560.6130.813.048.51%8.86%6.18%N/ANCLHNorwegian Cruise Line$910.26M$1.7313.6412.890.409.05%66.78%3.84%7/31/2025 (Estimated)REALRealReal-$134.20M-$1.13N/A∞N/A-6.60%N/A-10.99%8/7/2025 (Estimated)REGNRegeneron Pharmaceuticals$4.41B$39.2814.0014.472.0331.94%15.27%11.93%8/1/2025 (Estimated)Latest REGN, DKNG, EIDX, NCLH, HMSY, AMC, and REAL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025DKNGDraftKings$0.40N/AN/AN/A$1.39 billionN/A8/7/2025Q2 2025REALRealReal-$0.15N/AN/AN/A$159.17 millionN/A8/1/2025Q2 2025AMCAMC Entertainment-$0.07N/AN/AN/A$1.30 billionN/A8/1/2025Q2 2025REGNRegeneron Pharmaceuticals$8.53N/AN/AN/A$3.30 billionN/A7/31/2025Q2 2025NCLHNorwegian Cruise Line$0.51N/AN/AN/A$2.55 billionN/A5/8/2025Q1 2025REALRealReal-$0.13-$0.14-$0.01-$0.14$159.98 million$160.03 million5/7/2025Q1 2025AMCAMC Entertainment-$0.61-$0.58+$0.03-$0.47$983.23 million$862.50 million4/30/2025Q1 2025NCLHNorwegian Cruise Line$0.09$0.07-$0.02-$0.09$2.15 billion$2.13 billion4/29/2025Q1 2025REGNRegeneron Pharmaceuticals$8.83$8.22-$0.61$7.27$3.40 billion$3.03 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMCAMC EntertainmentN/AN/AN/AN/AN/ADKNGDraftKingsN/AN/AN/AN/AN/AEIDXEidos TherapeuticsN/AN/AN/AN/AN/AHMSYHMSN/AN/AN/AN/AN/ANCLHNorwegian Cruise LineN/AN/AN/AN/AN/AREALRealRealN/AN/AN/AN/AN/AREGNRegeneron Pharmaceuticals$3.520.64%N/A8.96%N/ALatest REGN, DKNG, EIDX, NCLH, HMSY, AMC, and REAL DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/20/2025REGNRegeneron Pharmaceuticalsquarterly$0.880.6%5/20/20255/20/20256/6/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMCAMC EntertainmentN/A0.420.42DKNGDraftKings2.111.201.20EIDXEidos Therapeutics0.1411.1011.10HMSYHMS0.264.714.71NCLHNorwegian Cruise Line9.090.190.16REALRealRealN/A0.870.76REGNRegeneron Pharmaceuticals0.094.934.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMCAMC Entertainment28.80%DKNGDraftKings37.70%EIDXEidos Therapeutics31.40%HMSYHMS95.83%NCLHNorwegian Cruise Line69.58%REALRealReal64.73%REGNRegeneron Pharmaceuticals83.31%Insider OwnershipCompanyInsider OwnershipAMCAMC Entertainment0.32%DKNGDraftKings51.19%EIDXEidos Therapeutics70.10%HMSYHMS2.70%NCLHNorwegian Cruise Line0.41%REALRealReal9.00%REGNRegeneron Pharmaceuticals7.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMCAMC Entertainment33,382431.95 million430.57 millionOptionableDKNGDraftKings5,100889.30 million434.07 millionOptionableEIDXEidos Therapeutics7038.87 millionN/ANot OptionableHMSYHMS3,10088.64 millionN/AOptionableNCLHNorwegian Cruise Line41,700446.81 million444.98 millionOptionableREALRealReal3,011113.09 million102.92 millionNot OptionableREGNRegeneron Pharmaceuticals15,106107.96 million100.39 millionOptionableREGN, DKNG, EIDX, NCLH, HMSY, AMC, and REAL HeadlinesRecent News About These CompaniesRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Bailard Inc.1 hour ago | marketbeat.comWealthfront Advisers LLC Sells 1,173 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)4 hours ago | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Boosted by Concord Wealth PartnersJuly 17 at 8:10 AM | marketbeat.comCullen Frost Bankers Inc. Has $4.36 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 17 at 7:13 AM | marketbeat.comUBS Raises Regeneron (REGN) Price Target, Maintains Neutral RatingJuly 16 at 12:20 AM | msn.comRegeneron Advances Melanoma Treatment with New Phase 2 TrialJuly 16 at 1:00 PM | tipranks.comRegeneron’s Innovative Approach in Follicular Lymphoma Treatment: A New Phase 3 TrialJuly 16 at 12:16 PM | tipranks.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Grandfield & Dodd LLCJuly 16 at 8:34 AM | marketbeat.comApollon Wealth Management LLC Has $2.22 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 16 at 5:59 AM | marketbeat.com1 Healthcare Stock on Our Buy List and 2 to Brush OffJuly 15 at 11:46 AM | finance.yahoo.comCenterBook Partners LP Sells 10,270 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 15 at 9:43 AM | marketbeat.comConcord Asset Management LLC VA Has $1.33 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 15 at 8:50 AM | marketbeat.comLeo Wealth LLC Has $748,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 15 at 6:47 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Sumitomo Life Insurance Co.July 15 at 6:32 AM | marketbeat.com685 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Asahi Life Asset Management CO. LTD.July 14, 2025 | marketbeat.comOVERSEA CHINESE BANKING Corp Ltd Invests $30.17 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 14, 2025 | marketbeat.comSlow Capital Inc. Buys 6,715 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 14, 2025 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Raised by Cutter & CO Brokerage Inc.July 14, 2025 | marketbeat.comMQS Management LLC Takes $450,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 14, 2025 | marketbeat.comNew York State Common Retirement Fund Sells 6,846 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 14, 2025 | marketbeat.comOxbow Advisors LLC Purchases New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend1999 Again? The Danger of These 3 Companies Making Bitcoin BetsBy Gabriel Osorio-Mazilli | July 8, 2025View 1999 Again? The Danger of These 3 Companies Making Bitcoin Bets5 Robotics Stocks to Buy for the Future of AutomationBy Ryan Hasson | July 14, 2025View 5 Robotics Stocks to Buy for the Future of AutomationTrump Tailwind? How the BBB Could Boost DraftKings StockBy Leo Miller | July 17, 2025View Trump Tailwind? How the BBB Could Boost DraftKings StockREGN, DKNG, EIDX, NCLH, HMSY, AMC, and REAL Company DescriptionsAMC Entertainment NYSE:AMC$3.49 +0.31 (+9.87%) Closing price 07/17/2025 03:59 PM EasternExtended Trading$3.48 -0.01 (-0.26%) As of 09:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AMC Entertainment Holdings, Inc., through its subsidiaries, engages in the theatrical exhibition business. It owns, operates, or has interests in theatres in the United States and Europe. The company was founded in 1920 and is headquartered in Leawood, Kansas.DraftKings NASDAQ:DKNG$43.94 +0.58 (+1.34%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$44.23 +0.29 (+0.66%) As of 09:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DraftKings Inc. operates as a digital sports entertainment and gaming company in the United States and internationally. It provides online sports betting and casino, daily fantasy sports, media, and other consumer products, as well as retails sportsbooks. The company also engages in the design and development of sports betting and casino gaming software for online and retail sportsbooks, and iGaming operators. In addition, it offers DraftKings marketplace, a digital collectibles ecosystem designed for mainstream accessibility that offers curated NFT drops and supports secondary-market transactions. The company is headquartered in Boston, Massachusetts.Eidos Therapeutics NASDAQ:EIDXEidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.HMS NASDAQ:HMSYHMS Holdings Corp., through its subsidiaries, provides cost containment solutions in the United States healthcare marketplace. The company offers coordination of benefits services to government and commercial healthcare payers to ensure that the correct party pays the claim; and population management solutions that provide risk-bearing organizations with intelligence across their member populations to identify risks, and enhance patient engagement and outcomes, as well as payment integrity, care management and consumer engagement, and analytical solutions. It serves state Medicaid programs, commercial health plans, federal government health agencies, government and private employers, children's health insurance program, and other healthcare payers, as well as a subcontractor. The company was founded in 1974 and is headquartered in Irving, Texas.Norwegian Cruise Line NYSE:NCLH$23.60 +0.55 (+2.37%) Closing price 07/17/2025 03:59 PM EasternExtended Trading$23.94 +0.35 (+1.47%) As of 09:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Norwegian Cruise Line Holdings Ltd., together with its subsidiaries, operates as a cruise company in North America, Europe, the Asia-Pacific, and internationally. The company operates through the Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises brands. It offers itineraries ranging from three days to a 180-days calling on various ports, including Scandinavia, Northern Europe, the Mediterranean, the Greek Isles, Alaska, Canada and New England, Hawaii, Asia, Tahiti and the South Pacific, Australia and New Zealand, Africa, India, South America, the Panama Canal, and the Caribbean. It distributes its products through retail/travel advisor and onboard cruise sales channels, as well as meetings, incentives, and charters. Norwegian Cruise Line Holdings Ltd. was founded in 1966 and is based in Miami, Florida.RealReal NASDAQ:REAL$5.64 +0.42 (+8.05%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$5.70 +0.06 (+0.98%) As of 08:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The RealReal, Inc. operates an online marketplace for resale luxury goods in the United State. The company offers various product categories, including women's fashion, men's fashion, jewelry, and watches. It primarily sells products through online marketplace and retail stores. The company was incorporated in 2011 and is headquartered in San Francisco, California.Regeneron Pharmaceuticals NASDAQ:REGN$550.00 +2.07 (+0.38%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$549.80 -0.20 (-0.04%) As of 08:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
